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Abstract
Using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to monitor vascular changes induced by
sunitinib within amurine xenograft kidney tumor, we previously determined a dose that caused only partial destruction
of blood vessels leading to “normalization” of tumor vasculature and improved blood flow. In the current study, kidney
tumorswere treatedwith this doseof sunitinib tomodify the tumormicroenvironment and enhance the effect of kidney
tumor irradiation. The addition of soy isoflavones to this combined antiangiogenic and radiotherapy approach was in-
vestigated based on our studies demonstrating that soy isoflavones can potentiate the radiation effect on the tumors
and act as antioxidants to protect normal tissues from treatment-induced toxicity. DCE-MRI was used to monitor vas-
cular changes induced by sunitinib and schedule radiation when the uptake and washout of the contrast agent indi-
cated regularization of blood flow. The combination of sunitinib with tumor irradiation and soy isoflavones significantly
inhibited the growth and invasion of established kidney tumors and caused marked aberrations in the morphology of
residual tumor cells. DCE-MRI studies demonstrated that the threemodalities, sunitinib, radiation, and soy isoflavones,
also exerted antiangiogenic effects resulting in increased uptake and clearance of the contrast agent. Interestingly,
DCE-MRI and histologic observations of the normal contralateral kidneys suggest that soy could protect the vascula-
ture of normal tissue from the adverse effects of sunitinib. An antiangiogenic approach that only partially destroys
inefficient vessels could potentially increase the efficacy and delivery of cytotoxic therapies and radiotherapy for
unresectable primary renal cell carcinoma tumors and metastatic disease.
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Introduction
The advent of targeted therapies has changed the paradigm of sys-
temic therapy for advanced metastatic renal cell carcinoma (RCC).
Extensive research is focusing on drugs that target both the tumor
cells and the tumor vasculature to inhibit processes in the tumor micro-
environment that stimulate tumor growth. The incidence of RCC has
increased in recent years with approximately 58,240 new cases each
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year in the United States. The disease is responsible for an estimated
13,040 deaths each year [1]. Nearly half of the patients present with
localized disease that can be treated by surgical removal [2]. However,
one third of the patients have metastatic disease at first presentation,
and 20% to 30% of the patients treated for localized RCC subsequently
develop metastatic disease which frequently involves the lungs [2,3].
Metastatic RCC disease has been resistant to chemotherapy and radio-
therapy with a patient median survival of only 8 to 11 months [2,3].
This poor responsiveness could be due to the high vascularity of RCC
tumors, which is structurally and functionally abnormal consisting of
enlarged, disorganized, and leaky vessels. These vascular features cause
impaired blood supply, decreased oxygen, and interstitial hypertension
in tumors compromising the delivery and efficacy of cytotoxic agents
and radiotherapy [4,5].
Recent treatments with new antiangiogenic drugs to disrupt tumor
vasculature have shown significant responses and improved survival
in RCC patients with metastatic disease [6–10]. Among others, small-
molecule receptor tyrosine kinases (RTKs) inhibitors target the receptors
of angiogenic factors including the vascular endothelial growth factor
(VEGF) produced by tumor cells and associated stromal cells [11,12].
The RTK inhibitors sunitinib and axitinib inhibit the signal transduc-
tion induced byVEGFbinding toVEGFreceptors (VEGFR). Sunitinib
also targets signaling of additional RTKs including platelet-derived
growth factor receptor (PDGFR), KIT, and FLT3 in mouse xenograft
models [11,13,14], whereas axitinib is a more selective RTK inhibitor
of all three VEGF receptors VEGFR-1, -2, and -3 [15,16]. We have
previously shown that sunitinib exhibits direct antitumor activity by in-
hibiting VEGFR-2 and PDGFR-β RTKs that are expressed on human
KCI-18 RCC cancer cells, a cell line established from an RCC tumor
specimen in our laboratory [11,17]. These RTKs are probably involved
in signaling for cancer cell proliferation as shown in other studies
[13,14]. Sunitinib also exhibits antiangiogenic activity by inhibition of
signaling through VEGFR-2 and PDGFR-β RTKs expressed on endo-
thelial or stromal cells [18,19].
Sunitinib has been approved by the US Food and Drug Administra-
tion in January 2006 for RCC treatment based on significant clinical
responses in metastatic sites and primary tumors and is currently used
as a front-line standard of care in metastatic RCC [10,19]. Sunitinib
increased the median survival to 28 months [10]; however, long-term
control of the disease is still not achieved, and the therapy is limited by
adverse effects of cardiotoxicity observed in some of the patients, prob-
ably because of alterations to normal vasculature [20,21]. Therefore, we
used the KCI-18 orthotopic xenograft murine tumor model to investi-
gate whether sunitinib can be used at lower and less toxic doses to regu-
larize the vasculature, decrease tumor vessel leakiness and interstitial
pressure, and improve the blood flow within the tumor [11]. Using
dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
to image vascular changes induced by sunitinib within a KCI-18 kidney
tumor in nude mice, we have previously shown that a suboptimal daily
sunitinib dose of 20 mg/kg per day mildly affected normal vessels but
caused better tumor perfusion and decreased vascular permeability, in
agreement with histologic observations of thinning and regularization
of tumor vessels [11]. These studies indicated that this dose and sched-
ule of sunitinib, which caused only partial destruction of inefficient
blood vessels, lead to “normalization” of tumor vasculature and im-
proved the tumor blood flow [11]. We further demonstrated that
scheduling chemotherapy with gemcitabine, at a time when the blood
flow is improved by pretreatment with sunitinib, resulted in enhanced
therapeutic response [12].
In the current studies, the combination of the antiangiogenic drug
sunitinib with kidney tumor irradiation and soy isoflavones was inves-
tigated to induce greater tumor cell killing and prolong the therapeutic
response. The rationale for selecting soy isoflavones as anticancer agents
is based on our previous studies showing that these compounds cause
tumor cell apoptosis and also sensitize cancer cells to radiation both
in vitro and in vivo in preclinical orthotopic models of RCC and pros-
tate cancer [17,22–27]. Soy isoflavones are safe natural anticancer agents,
as demonstrated in clinical trials [28], and they can also act as anti-
oxidants in normal tissues and protect them from treatment-induced
toxicity. A recent clinical trial for prostate cancer patients showed that
soy isoflavones pills, taken in conjunction with radiotherapy, reduced
radiation toxicity to normal tissues including urinary, gastrointestinal,
and sexual functions [29]. Therefore, we also tested whether soy isofla-
vones could enhance the therapeutic effect of sunitinib combined with
radiotherapy while reducing toxicity to normal organs.
The combination of the antiangiogenic drug sunitinib at a sub-
optimal dose of 20 mg/kg per day with tumor irradiation and soy iso-
flavones significantly inhibited the growth and invasion of established
kidney tumors and caused marked aberrations in the morphology of
residual tumor cells. DCE-MRI studies demonstrated that the three
modalities, sunitinib, radiation, and soy isoflavones, also exerted anti-
angiogenic effects resulting in increased uptake and clearance of the
contrast agent. In addition, DCE-MRI and histologic observations of
the normal contralateral kidneys suggest that soy could protect the vas-
culature of normal tissue from adverse effects of sunitinib.
Materials and Methods
Orthotopic KCI-18/IK RCC Tumor Model
The human RCC cell line designated KCI-18 was established in our
laboratory from a primary renal tumor specimen obtained from a pa-
tient with papillary RCC (nuclear grade 3/4) [17]. Cells were cultured
inDulbecco modified Eagle mediumwith supplements and serially pas-
saged in the kidney of nude mice in vivo to generate highly tumorigenic
KCI-18/IK cell lines, as previously detailed [17]. KCI-18/IK cells were
washed with Hank’s balanced salt solution and subcapsularly injected at
a concentration of 5 × 105 cells in 30 μl of Hank’s balanced salt solution
in the right kidney in 5- to 6-week-old female BALB/C nu/nu nudemice
(Harlan, Indianapolis, IN) [17]. Mice were housed and handled under
sterile conditions in facilities accredited by the American Association for
the Accreditation of Laboratory Animal Care. The animal protocol was
approved by Wayne State University Animal Investigation Committee.
Reagents
Sunitinib (Pfizer, Inc, New York, NY) was prepared in a carboxy-
methyl cellulose suspension vehicle, at a dosage of 20 mg/kg per day
(SU20) and given orally by gavage, once a day [11]. The soy isoflavones
mixture G-4660 consisted of 83.3% genistein, 14.6% daidzein, 0.26%
glycitein, with the remainder being carbohydrate (manufactured by
Organic Technologies and obtained from the National Institutes of
Health). The soy isoflavones mixture was dissolved in 0.1 M Na2CO3
and mixed with sesame seed oil at a 2:1 ratio just before treatment to
facilitate gavage and avoid irritation of the esophagus by Na2CO3
[25]. Mice were treated with 1 mg/d of soy (50 mg/kg body weight
per day) by gavage.
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Tumor-Bearing Kidney Irradiation
Three anesthetizedmice, in jigs, were positioned under a 6.4-mm lead
shield with three cut outs in an aluminum frame mounted on the x-ray
machine to permit selective irradiation of the right tumor-bearing
kidneys in three mice at a time, as previously described [17]. The radia-
tion dose to the kidney and the scattered dose to areas of the mouse out-
side the radiation field were carefully monitored. Photon irradiation was
performed at a dose of 8Gy with a Siemens Stabilipan X-ray set (Siemens
Medical Systems, Inc, Malvern, PA) operated at 250 kV, 15 mA with
1-mm copper filtration at a distance of 47.5 cm from the target.
Experimental Protocol
After injection of KCI-18/IK cells in the kidney, a few mice were
killed at early time points to assess tumor growth before initiating treat-
ment. The tumor-bearing kidneys were weighed and measured in three
dimensions to calculate the volume using length × width × thickness ×
0.5236 / 2. Small tumors were established by day 10, andmeasurements
of tumor-bearing kidneys were 150 mm3 (SD, 7) volume and 186 mg
(SD, 4) weight comparedwith normal kidney sizes of 125mm3 (SD, 2),
148 mg (SD, 12) [11]. On day 10, mice were pretreated each day for
3 days with soy isoflavones first given at 1 mg and, 6 hours later, with
sunitinib given at 20 mg/kg; both drugs were administered orally by
gavage [11,17,25]. Radiation was administered on day 13 at 8 Gy and
targeted to the area of the right tumor-bearing kidney [17]. Sunitinib
and/or soy treatments were continued daily for the duration of the
experiment. To assess the therapeutic response of kidney tumors to
sunitinib, soy, and radiation, eight mice per experimental group were
treated. Mice were killed by day 27 after tumor cell injection, when
the tumor burden in control animals was large (>1.5 cm × 1 cm in size
compared with 0.7 cm × 0.25 cm for normal kidney) to compare with
tumor sizes in treated groups [11]. The tumor-bearing right kidneys and
the contralateral left normal kidneys were resected and weighed [11,12].
Tissue Preparation for Histology
At the completion of experiments, mice were killed, and tumor-
bearing kidneys, normal contralateral kidneys, and the lungs were re-
sected and processed for histology. All tissues were fixed in 10% buffered
formalin, embedded in paraffin, and sectioned [11]. Sectionswere stained
with hematoxylin-eosin (H&E) or immunostainedwith anti-CD31 anti-
body (Ab) (Thermo Scientific, Fremont, CA) using an avidin-biotin-
immunoperoxidase technique [11].
DCE-MRI Monitoring of Tumor Perfusion and
Permeability in Kidney Tumors
Mice treatedwith single or combined treatments of sunitinib, soy, and
radiation were imaged by DCE-MRI, as previously detailed [11,12]. A
catheter was inserted into mice tail vein and was attached to a syringe
containing Gd-DTPA contrast agent (Berlex,Wayne, NJ). Anesthetized
mice were positioned on a cradle heated by temperature-controlled
water [11,12]. A 2-cm-diameter receive-only surface coil was placed
over the tumor, and the cradle was placed inside an 11-cm-inner-
diameter transmit-only volume coil for imaging using a Bruker Biospec
AVANCE animal scanner (Bruker, Karlsruhe, Germany) equipped with
a 4.7-T horizontal bore magnet and actively shielded gradients. Baseline
imaging data of the kidneys were obtained using the short TR DCE
scan for 30 time points (7 seconds between time points). On time point
10, 100 μl of Gd-DTPA (0.125mmol/kg) was injected into the tail vein
catheter. Then, imaging data were acquired for 20 more time points.
The imaging parameters for this multislice two-dimensional gradient
echo scan were as follows: repetition time = 54.7 milliseconds, echo
time = 2.9 milliseconds, flip angle = 30°, field of view = 32 mm ×
32 mm, slice thickness = 1.5 mm with 0.5-mm gap, matrix size =
128 × 128. Five slices were collected for each animal. Data were pro-
cessed to determine changes in contrast agent uptake using the SPIN
DCE software (Detroit, MI) [11,12]. For data analysis, the full kid-
ney was selected as the region of interest (ROI) for the tumor-bearing
kidney and the contralateral left normal kidney. A threshold was set
at three times (3×) the noise to remove noise-only pixels in the image
[11]. Gd concentrations [C(t)] in the tissue were calculated for all pixels in
the ROI and for each time point [11]. Data from the C (t) curves were
compiled for each pixel for nine time points (63 seconds) after Gd in-
jection to create the initial area under the curve (IAUC). The CIAUC
is the cumulative initial area under the curve of the IAUChistogram [11].
To evaluate the uptake, washout, and leakage of Gd into the tumor and
surrounding kidney tissue, T1-weighted images and AUC parametric
maps serve as a means to enhance tumor visibility, quantify Gd con-
centration, and monitor changes in vascular response.
Analysis of Cell Survival In Vitro by Clonogenic Assay
The radiation dose and drug concentrations were determined based
on our previous studies [11,23]. KCI-18 human RCC cells were pre-
treated for 24 hours with 1 μM sunitinib and/or 5 μM soy isoflavones
and then irradiated with 3-Gy photons as previously described [11,23].
Single and combined treatments were tested. For comparison between
each treatment group, the number of treated cells plated in the clono-
genic assay was adjusted relative to untreated cells to predict a mea-
surable survival fraction, as determined in pilot experiments. Cells
were plated in a colony formation assay in triplicate wells of six-well
plates at 500 cells per well for control; 1000 cells per well for sunitinib,
soy, or radiation alone; 2000 cells per well for sunitinib + soy; 3000 cells
for radiation + sunitinib, radiation + soy; and 4000 cells for radiation +
sunitinib + soy [11,12,23]. The drugs were added to the cells in the
colony plates, and cells were incubated for 10 days at 37°C in a 5%
CO2/5% O2/90% N2 incubator. Colonies were fixed, stained, and
counted as previously described [11]. The plating efficiency was calcu-
lated for each well by dividing the number of colonies by the original
number of cells plated. The surviving fraction (SF) was normalized
to control cell plating efficiency by dividing the plating efficiency of
treated cells by that of control cells [11]. The plating efficiency was
calculated for each well, and the surviving fraction was normalized to
control cells [11].
Statistical Analysis
Evaluation of the shape of the frequency distribution of tumor
weights indicated that a log transformation was required to meet the
assumptions of normal theory tests. Linear models were used to assess
the statistical significance of differences in tumor weight between ex-
perimental groups. Adjustment formultiple comparisons between treat-
ments was made using Holm’s procedure to protect against inflated
type 1 errors [11,12].
Results
Enhanced Cytotoxic Effect of Sunitinib, Soy Isoflavones,
and Radiation in KCI-18 Cells In Vitro
A dose of 1 μM sunitinib caused 37% inhibition in KCI-18 cell sur-
vival in a clonogenic assay (Table 1) [11]. This dose was selected to in-
vestigate whether cell killing is enhanced by the addition of soy and
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radiation. After pilot titration experiments, suboptimal doses of soy
and radiation were tested alone and combined with sunitinib in a clono-
genic assay to assess whether the combination is more effective at cell
killing. A low dose of 5 μM of the mixture of soy isoflavones caused
25% (SD, 5) inhibition in cell survival but significantly increased the
effect of sunitinib to 56% (SD, 2) inhibition (P < .002) compared with
sunitinib alone (Table 1). Cells irradiated with 3-Gy photons showed
a 56% (SD, 4) inhibition in cell growth that was further significantly
enhanced to 74% to 80% (SD, 2.3) by cotreatment with sunitinib or
soy isoflavones or both (P < .05; Table 1).
Enhanced Therapeutic Response of Kidney Tumors by
Combined Sunitinib, Radiation, and Soy In Vivo
We previously showed that a dosage of 20 mg/kg per day sunitinib
caused regularization of tumor vessels with improved tumor perfusion
[11]; therefore, this dosage was selected for combination with radio-
therapy. To schedule the combination therapy, regularization of tumor
vessels was monitored by DCE-MRI of kidney tumor–bearing mice
treated with sunitinib only. On day 10 after tumor implantation, mice
with established kidney tumors were treated daily with sunitinib at
20 mg/kg per day (SU20) for 1 or 3 days and then imaged by DCE-
MRI (Figure 1A). As previously observed, a slower clearance of Gd
was observed in the tumor-bearing kidney, with the CIAUC curve
shifting to the right of the normal kidney (Figure 1) [11]. After 1 day
of SU20 treatment, a shift of the tumor-bearing kidney IAUC and
CIAUC curves toward those of normal kidney was observed. However,
the effect of a 3-day treatment with SU20 was more pronounced as the
kidney tumor showed identical patterns of Gd uptake and clearance
than those of the normal kidney. The IAUC and CIAUC histograms
of the kidney tumor overlapped those of the normal kidney, indicating
decreased Gd retention and improved tumor perfusion (Figure 1), as
previously described [11].
On the basis of these data demonstrating vascular regularization
by DCE-MRI after three daily doses of SU20 treatment, irradiation
(Rad) of the tumor-bearing kidney was administered at that time point,
on day 13, as shown in Figure 2A. We had shown that pretreatment
with soy potentiates the effect of radiation in kidney and prostate
tumors; therefore, soy treatment was also initiated on days 10 to 12 be-
fore radiation. Both SU20 and soy treatments were continued daily
after radiation up to day 27 when mice were killed to assess tumor re-
sponse (Figure 2B). Compared with control kidney tumors (mean ± SD
weight, 771 ± 413mg), treatments with soy alone (P = .03), SU20 alone
(P = .04), and radiation alone (P = .008) caused a significant decrease of
tumor growth, but these tumors were still very large with a mean weight
range of 400 to 470 mg (Figure 2B). However, the combinations of
soy + Rad, SU20 + Rad, and SU20 + Soy + Rad caused a much greater
and significant inhibition of tumor growth with weights in the range of
190 to 320 mg compared with control mice (P < .001; Figure 2B). Al-
though combining the three modalities soy, sunitinib, and radiation was
borderline significant to two modalities (P = .06), it still resulted in a
more consistent and almost 97% complete inhibition of tumor growth,
with a mean tumor weight of 187 ± 46mg compared with 174 ± 25mg
of the normal kidneys nonbearing tumors. The combination of soy,
SU20, and radiation narrowed the range of tumor-bearing kidney sizes
compared with SU20 + Rad or Soy + Rad, and these values were very
close and not statistically different from those of normal kidneys (NK)
(P = .77; see broken line at 200 mg in Figure 2B), suggesting dramatic
tumor growth inhibition. Indeed, mice treated with SU20 + Rad + Soy
had very small tumor-bearing kidneys (KT) that approximated the size
and appearance of normal kidneys compared with the large tumors in
control mice (Figure 2B, inset). No signs of toxicity were observed in
these mice.
In Situ Effects of Sunitinib, Radiation, and Soy on KTs
Histologic samples of the kidney tumors obtained from mice treated
with SU20, soy, and radiation were processed for histology and H&E
staining. Kidney tumors from control mice consisted of cells with large
pleomorphic nuclei and were highly vascularized with a sinusoidal vas-
cular pattern and abnormal enlarged vessels (Figure 3, A and B) [11].
After SU20 and kidney tumor irradiation, small nodules of tumor were
seen surrounded by normal kidney tissue consisting of typical tubules
and glomeruli (Figure 3A). These tumor nodules contained atypical
giant tumor cells or detached rhabdoid cells with large vacuoles (Fig-
ure 3B), which are characteristic of radiation-induced alterations, as
previously described [17]. Kidney tumors treated with SU20, tumor
irradiation, and soy isoflavones showed comparable findings with very
small remaining tumor nodules surrounded by normal kidney tissue
(Figure 3A). The residual tumor areas had hemorrhages and consisted
mostly of detached rhabdoid cells with large vacuoles and atypical giant
cells with pleomorphic nuclei often undergoing degenerative changes
(Figure 3B). These data are indicative of slow death due to alterations
in cell division at the level of cytokinesis, as previously described
[22,25]. These changes are similar to those previously observed in
KCI-18 kidney tumors treated with genistein and radiation and there-
fore reflect further tumor destruction by soy and radiation [17].
The systemic effects of SU20 and soy isoflavones on the vasculature
of normal tissues were studied on the contralateral left normal kidney
not bearing a tumor, which was not irradiated. The normal kidney
tissue sections shown in Figure 4 were obtained from untreated mice;
mice treated with SU20 + Rad (labeled SU20 in Figure 4) or SU20 +
Soy + Rad (labeled SU20 + Soy in Figure 4) only reflect the alterations
induced by SU20 or soy isoflavones because they were not in the field
of radiation. The H&E observations (Figure 4A) were confirmed by
anti-CD31 immunostaining of endothelial cells (Figure 4B). Compared
with thin and regular vessels in normal kidneys of control mice, the
normal kidney vessels of mice treated with SU20 showed mild dilata-
tion, both by H&E and immunostaining with anti-CD31 (Figure 4,
A and B), as previously seen for SU20 (Figure 4) [11]. The vessels of
normal left kidneys from mice treated with SU20 and soy isoflavones
looked thinner and more regular, as confirmed by anti-CD31 staining
(Figure 4, A and B).
Table 1. Inhibition of KCI-18 Cell Growth by Sunitinib Combined with Soy and Radiation In Vitro.
Treatment Survival Fraction (Mean ± SD) % Inhibition (Mean ± SD)
Control 1 ± 0 0 ± 0
SU 0.63 ± 0.04 37 ± 7
Soy 0.75 ± 0.07 25 ± 4
SU + soy 0.44 ± 0.02 56 ± 2
Rad 0.44 ± 0.04 56 ± 4
Rad + SU 0.26 ± 0.03 74 ± 3
Rad + soy 0.23 ± 0.02 77 ± 2
Rad + SU + soy 0.20 ± 0.02 80 ± 3
KCI-18 cells were treated with sunitinib at 1 μMor soy at 5 μMor both drugs for 24 hours, and then
cells were irradiated with 3-Gy photons and plated in a colony formation assay for 10 days. The mean
survival fraction (SF) was calculated from triplicate wells. The percent inhibition was calculated as
follows: SF (control) − SF (treatment) / SF (control) × 100.
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DCE-MRI Evaluation of Vascular Changes Induced by
Sunitinib, Soy, and Radiation Treatments in Kidney Tumors
Established KCI-18 kidney tumors were pretreated with SU20 and
soy isoflavones on days 10 to 12. On day 13, the right kidneys bear-
ing KCI-18 tumors were irradiated with 8 Gy. On days 14, 15, and
16, sunitinib and soy treatments were resumed. On day 17, i.e., 4 days
after irradiation and six daily treatments with sunitinib and soy, mice
were imaged by DCE-MRI (T1-weighted images shown in Figure 5A),
before and after Gd injection (Figure 5A–E ). Data from C (t) curves
(Figure 5B) of the kinetics of Gd concentrations were compiled for nine
time points after Gd contrast injection to create IAUC (Figure 5C) and
CIAUC (Figure 5D) histograms. Images of the first nine time points
after Gd injection were selected for constructing IAUC andCIAUChis-
tograms because MR images showed early and rapid drastic changes in
Gd uptake and clearance within these time intervals, in treated tumors
compared with control tumors and relative to normal kidneys. Control
tumors showed slower Gd clearance and a shift of IAUC and CIAUC
curves to the right of the normal kidney curves. No uptake of Gd in the
core of the kidney tumor was seen in AUCparametricmaps (Figure 5E).
Kidney tumors treated with radiation alone or combined with SU20
and soy showed a pattern of uptake and clearance of Gd in C(t) curves
parallel to that of normal kidney with improved kinetics of Gd clearance
(Figure 5B). A shift to the left in IAUC histograms and a narrower dis-
tribution compared with that of control tumors indicated an improved
Gduptake and clearance (Figure 5C ), as confirmed byGd tumor uptake
in AUC parametric maps (Figure 5E ). Treatment with SU20 alone or
combined with radiation showed IAUC and CIAUC patterns of kidney
tumors overlapping with those of normal kidneys in these mice, con-
firming the effect of SU20 on regularization of blood flow in kidney
tumors (Figure 5, B–D). However, as previously observed, SU20 caused
vascular changes in the normal left kidney visualized as a wider IAUC
peak and a shift to the right of the IAUC curve compared with that
seen in the normal kidney of control mice. This effect was also seen
in the left normal kidney (nonirradiated) of mice treated with SU20
and radiation, thus reflecting only SU20 treatment of normal vessels
(Figure 5C ). Interestingly, when mice were treated with both systemic
soy and SU20 treatments in addition to the right kidney tumor irradia-
tion, the left normal kidney exhibited a normal uptake, and clearance of
Gd contrast agent similar to that of the normal kidney of control mice or
mice treated with radiation only (Figure 5C , see arrow in the IAUC
curve). The wider distribution of IAUC and the shift of IAUC to the
right seen with SU 20 alone were not observed when soy was added.
To determine further the effect of soy on vessels of normal tissues and
tumors, mice treated with soy alone and combined either with SU20 or
radiation were imaged byDCE-MRI. The IAUC andCIAUC shift rela-
tive to normal kidney curves was reduced by soy treatment alone (Fig-
ure 6, B and C), which also caused an increased uptake of Gd contrast
in the tumor observed in AUC parametric maps, which is indicative of
soy mediating a regularizing effect on tumor vasculature (Figure 6D).
The left normal kidney showed a normal pattern ofGduptake and clear-
ance. Soy combined with SU20 induced vascular changes in the kidney
tumor comparable to those observed with SU20 alone with a shift of
IAUC and CIAUC curves toward those of the normal kidney (Figure 6,
B andC).However, in contrast to SU20 alone, the pattern of Gd uptake
and clearance in the left normal kidney of Soy + SU20 (Figure 6B) re-
sembled that of control mice or soy-only–treated mice, confirming that
Figure 1. DCE-MRI of early vascular changes induced by sunitinib. Mice bearing established kidney tumors were treated with sunitinib at
20 mg/kg per day for 1 day (SU20 ×1) and on a daily basis for 3 days (SU20 ×3) and imaged by DCE-MRI.
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soy regularized Gd flow in the normal kidney andmitigated the vascular
changes induced by SU20 alone. Vascular regularization visualized by
overlapping and shifted curves was also observed in the kidney tumors
of mice treated with soy and radiation, suggesting that soy and radiation
regularized the tumor vasculature (Figure 6, B and C). These findings
are in agreement with the AUC parametric maps showing Gd uptake in
tumors. Although a representative mouse is shown for each treatment,
presented in Figures 5 and 6, these data were reproduced and consistent
in additional mice and two series of independent experiments.
To compare the patterns of Gd uptake in tumor-bearing kidneys
versus normal kidneys, R50 values were derived from the CIAUC curves
for both kidney tumors and normal kidneys (Figures 5 and 6). The R50
(median) values correspond to the concentration of Gd at which 50% of
the pixels have been included [11]. R50 values of KTs were then normal-
ized to the R50 values of NKs for each mouse, as detailed previously
[11,12]. The means and SDs of normalized R50 values (NR50) for four
mice per treatment group are presented in Table 2. These quantitative
data confirm that mice treated with SU20 alone and SU20 combined
with soy or radiation had NR50 values near zero (P < .005 compared
with control) owing to similar distributions of IAUCandCIAUCcurves
for KTand NK as seen in Figures 5 and 6. Interestingly, soy combined
with radiation also had low values of NR50 (P < .05 compared with
control) because they both destroy some of the tumor vasculature caus-
ing normalization as visualized by overlapping IAUC and CIAUC
Figure 2. KCI-18 kidney tumor response to sunitinib combinedwith radiation and soy. (A) Treatment schedule for combination therapy. Mice
bearing established kidney tumors were pretreated with sunitinib at 20 mg/kg per day (SU20) and/or soy at 50 mg/kg per day for 3 days, on
days 10 to 12 after KCI-18 cell injection in the kidney. Then, mice received an 8-Gy radiation to the tumor-bearing kidney. Sunitinib and/or soy
were continued daily for up to 27 days. (B) Response of tumor-bearing kidneys to single and combined therapy. On day 27, tumor-bearing
kidneys and contralateral normal kidneys were resected and weighed. The weights of the tumor-bearing kidneys and their median are re-
ported for eight mice per group treated with vehicle (control) or SU20 or soy (Soy) or radiation (Rad) as single modalities and radiation com-
bined with SU20, soy, or both (*P< .05, **P< .001 compared with control mice). The normal contralateral kidney weights (NK) are shown.
Inset shows the size of kidney tumors before and after resection of control mice; mice treated with radiation and SU20; and mice treated
with radiation, SU20, and soy (Su + R + S) compared with normal kidney size.
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curves of KT and NK (Figure 6). Soy alone or radiation alone had
greater NR50 values comparable to those of control mice (P > .05),
although they affected tumor vasculature but probably not enough
to get normalization (Figures 5 and 6). When SU20 was combined
with radiation and soy, soy mitigated the effect of SU20 on normal
kidney vessels, which now show a normal pattern of uptake and clear-
ance of Gd. All three modalities regularize the uptake and clearance of
Gd with a narrower IAUC distribution, increased clearance but still do
not overlap with the normal kidney resulting in a greater NR50 value
(Table 2 and Figure 5).
Discussion
Antiangiogenic therapy causing excessive vascular regression could com-
promise the delivery of drugs or oxygen in the tumor and disrupt the ves-
sels of normal tissues. A combined approach consisting of antiangiogenic
Figure 3. Histology of kidney tumors from mice treated with sunitinib, radiation and soy. Kidney tumors from control mice or mice treated
with SU20 and kidney tumor irradiation (SU20 + Rad) and SU20 combined with radiation and soy (SU20 + Rad + Soy), obtained on day 27
from experiments described in Figure 2, were processed for histology and H&E staining. The main findings were labeled on the prints with
T for tumor, V for vessels, NKT for normal kidney tissue, H for hemorrhages, and G for giant cells. A lower magnification 20× is shown in
panel A and a higher magnification of 40× is shown in panel B to emphasize the findings. Control untreated tumors consisted of tumor cells
with large pleomorphic nuclei, were highly vascularized with a sinusoidal vascular pattern of abnormal enlarged dilated vessels (A, B). Kidney
tumors treated with SU20 + Rad showed small tumor nodules consisting of atypical giant tumor cells or detached rhabdoid cells with large
vacuoles (B). These nodules were surrounded by normal kidney tissue (NKT) consisting of typical tubules and glomeruli (A). Small remaining
tumor nodules treated with SU20 + Rad + Soy consisted mostly of abnormal degenerating giant tumor cells including focal hemorrhages
and were surrounded by normal kidney tissues (A, B).
116 Sunitinib, Radiation and Soy for RCC Hillman et al. Translational Oncology Vol. 4, No. 2, 2011
drugs to disrupt the tumor vasculature, given in conjunction with ra-
diation and cytotoxic agents to kill tumor cells, could be more effective
at preventing progression and/or recurrence of tumors in metastatic
RCC. The key to its success is to determine optimal scheduling and
dosing of antiangiogenic therapy with radiation and/or cytotoxic
agents for taking advantage of a time point in which normalization
of the structure of blood vessels caused by antiangiogenic therapy will
facilitate access of drugs and oxygen to tumor cells [30]. The goals of
the current studies were to monitor partial destruction of tumor vas-
culature to improve the blood flow with sunitinib and schedule radio-
therapy combined with soy isoflavones for RCC murine xenograft
kidney tumors.
DCE-MRI was selected to detect early changes in the tumor induced
by sunitinib as it measures a combination of tumor perfusion and vessel
permeability and allows the detection of early changes in tumor vas-
cularity induced by treatment with antiangiogenic drugs [31]. In the
current study, DCE-MRI showed that at least three consecutive daily
treatment with SU20 were sufficient to induce vascular changes of
decreased Gd retention and improved tumor perfusion in KCI-18
kidney tumors, which were comparable to those of the normal contra-
lateral kidney. On the basis of these findings indicating normalization of
blood vessels, radiation was administered to the kidney tumor after
three daily treatments of sunitinib. The effect of combined sunitinib
and radiation on inhibition of kidney tumor growth was enhanced
compared with each modality alone. Pretreatment with soy isoflavones
also significantly increased tumor growth inhibition by radiation as pre-
viously observed with pure genistein, which is the active compound of
soy [17]. Pretreatment with sunitinib and soy for 3 days followed by
Figure 4. Histology of normal kidneys frommice treated with sunitinib and soy. The normal contralateral kidneys from control mice or mice
treated with SU20 and SU20 combined with soy (SU20+ Soy), obtained on day 27 from experiments described in Figure 2, were processed
for histology and H&E staining (A) and anti-CD31 immunostaining (B). Only alterations induced by SU20 or soy can be observed in these left
kidneys because theywere not in the field of radiation. The normal kidney fromcontrolmice showed intact, regular, and thin blood vessels (A,
B). The vessels in normal kidneys of mice treated with SU20 showed mild dilatation (A, B). In contrast, the vessels of normal left kidneys
treated with systemic SU20 and soy looked thinner and more regular (A) as confirmed by anti-CD31 staining of endothelial cells (B).
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Figure 5. DCE-MRI imaging of vascular changes induced by sunitinib, radiation and soy in KCI-18 kidney tumors. Separate experimental
groups of three mice per group were treated with vehicle only (control), SU20, Rad, and Soy. Mice bearing established kidney tumors were
pretreatedwith sunitinib at 20mg/kg per day and soy at 50mg/kg per day for 3 days, on days 10 to 12 after KCI-18 cell injection in the kidney.
On day 13, the right kidneys bearing KCI-18 tumors were irradiatedwith 8 Gy. SU20 and soywere continued daily on days 14, 15, and 16, and
on day 17, mice were imaged by DCE-MRI and data were analyzed. (A) T1-weighted images (T1 WI): Baseline images before Gd contrast
agent injection. The full kidney was selected as the ROI for the tumor-bearing kidney (blue contour on left of T1-weighted image) and the
contralateral normal kidney (red contour on right of T1-weighted image). (B)C (t) kinetics ofGd contrast uptake and clearance: The first 10 time
points represent baseline data. Gd was injected at time point 10, and images were collected for 20 more time points. (C) IAUC graphs: Data
from theC (t) curveswere compiled for nine time points (63 seconds) after Gd injection to draw IAUC63. The small black bar indicates the peak
position of normal kidney in control mice, and this can be used as a reference for curve shifting in normal kidneys and kidney tumors after
treatment. (D) CIAUC graphs: CIAUC graphs were derived from IAUC curves. In B, C, and D graphs, blue lines are for kidney tumors and pink
lines are for normal kidneys. Data from a representative mouse from each treatment group are presented. (E) AUC parametric map: Para-
metric colormapswere constructedbasedonuptakeand concentration ofGd in the tissue, representedby thecolorsblue, green, yellow, and
redwithgradual increaseofGd from lowest values (0 for blue) to highest values (1 for red). This scale represents a normalized ratio obtainedby
dividing eachAUC value in an individual structure by themaximumAUCvalue in the overall image. The tumor-bearing kidney is on the left, and
the normal contralateral kidney is on the right of the MR images. The color coding in the kidneys is shown for integrated AUC.
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tumor irradiation and continued daily treatment with soy and sunitinib
was particularly effective, causing almost complete inhibition of tumor
growth. This effect was consistent in all mice treated, and the size and
shape of the tumor-bearing kidneys were comparable to those of the
normal contralateral kidneys. In agreement with our gross observations,
only small residual tumor nodules surrounded by normal kidney tissue
were histologically observed. These tumors showed a high frequency of
abnormal giant tumor cells with degenerative changes in their cytoplasm
and nuclei, indicative of cell death processes, as previously described
[17]. In mice treated with sunitinib and radiation, the nonirradiated
normal left kidney showed mild dilatation of normal vessels, reflect-
ing only sunitinib-induced vascular effects, as previously observed
[11]. Interestingly, addition of soy to sunitinib seems to protect the ves-
sels from dilatation because the vessels in the normal kidney tissue
looked thinner and more regular akin to those observed in control mice.
Previous studies indicated that soy isoflavones inhibited apoptosis in
endothelial cells and have shown benefits for the prevention of cardio-
vascular disease [32].
A direct and enhanced cytotoxic effect sunitinib, radiation, and soy
on KCI-18 cells was mediated in vitro, as shown in a clonogenic assay,
which could contribute to the enhanced therapeutic effect mediated
Figure 6. DCE-MRI imaging of vascular changes induced by soy combined with sunitinib or radiation in KCI-18 kidney tumors. In separate
experiments, mice bearing established kidney tumors were treated with soy, soy + SU20, or soy + Rad using the schedule and doses de-
scribed in Figure 5. Mice were imaged by DCE-MRI on day 17. (A) T1-weighted images (T1 WI): Baseline images before Gd contrast agent
injection as described in Figure 5. (B) IAUC graphs: Data from the C (t) curves were compiled for nine time points after Gd injection to draw
IAUC63. (C) CIAUC graphs: CIAUC curveswere derived from IAUC curves. In A, B, and C panels, blue lines are for kidney tumors and pink lines
are for normal kidneys. (D) AUCparametricmap: Parametric colormapswere constructed as described in Figure 5. The tumor-bearing kidney
is on the left and the normal contralateral kidney is on the right of theMR images. The color coding in the kidneys is shown for integratedAUC.
Data from a representative mouse from each treatment group are presented.
Table 2. NR50 Quantitation of DCE-MRI Data for KCI-18 Kidney Tumors.
Treatment *NR50 [KT vs NK] (Mean ± SD)
Control 0.22 ± 0.08
SU 0.01 ± 0.05
SU + soy −0.08 ± 0.07
Rad + SU 0.01 ± 0.04
Rad + SU + soy 0.21 ± 0.03
Soy 0.18 ± 0.08
Rad 0.19 ± 0.09
Rad + soy 0.08 ± 0.09
To calculate NR50, the R50 values for KTs and NKs were derived from CIAUC curves, which corre-
spond to the Gd concentration at which 50% of the pixels have been included. R50 values of KTwere
normalized to R50 values of NK and represent *NR50 [KT vs NK] calculated as [R50KT − R50NK] /
R50NK for each mouse. The mean NR50 for four mice per group is shown with SD.
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in vivo in kidney tumors by these three modalities. In addition to the
histologic findings in kidney tumors, DCE-MRI studies confirmed
that all three modalities also exert antiangiogenic effects and affect
the vascular properties of tumors. Kidney tumors treated with radiation
alone showed an improved uptake and clearance of Gd compared with
control untreated tumors, which was confirmed by better tumor per-
fusion seen in AUC parametric maps. These DCE-MRI data indicate
that radiation induces vascular changes in tumors, probably by killing
excess endothelial cells and disrupting blood vessels that are histologi-
cally visualized as hemorrhages. The pattern of Gd uptake and clearance
in kidney tumors treated with SU20 and radiation was similar to that of
tumors treated with SU20 alone with IAUC curves overlapping those
of the normal left kidney [11]. These data confirm the effect of SU20
on regularization of blood flow in kidney tumors [11]. Interestingly,
treatment of tumors with soy isoflavones alone also caused dramatic
vascular changes regularizing Gd uptake and clearance and improving
tumor perfusion akin to that observed in the normal kidney. A similar
effect was observed when soy isoflavones were combined with radiation
or sunitinib. These data suggest that soy isoflavones play an antiangio-
genic role in tumors by disrupting tumor vasculature, corroborating our
previous findings on VEGF inhibition in vitro [26]. Soy isoflavones’
antiangiogenic effect has been documented in other studies in vivo in-
cluding our studies in prostate tumors and RCC tumors [17,22,25].
AUC parametric maps showed increased perfusion in tumors treated
with sunitinib, radiation, and soy isoflavones, suggesting that these
three modalities induce significant vascular changes in the tumor envi-
ronment. Our studies also confirm that DCE-MRI can detect early vas-
cular changes in kidney tumors induced by sunitinib, radiation, soy
isoflavones, and the combination of these modalities.
DCE-MRI monitoring of vascular changes induced by soy isofla-
vones in the normal left kidney revealed that soy does not affect the
vascular flow compared with normal untreated kidney from control
mice. It is interesting to note that unlike the mild vascular changes ob-
served with SU20 systemic treatment in the left kidneys, mice receiving
both systemic SU20 and soy isoflavones exhibited a normal pattern of
Gd uptake and clearance akin to that of normal untreated kidney from
control mice. Thus, addition of soy isoflavones to SU20 regularized Gd
uptake and clearance in normal kidney and mitigated the vascular
changes induced by SU20 alone. These results are in agreement with
our in situ histologic observations of thinner and regular vessels. These
novel findings suggest that sunitinib-induced vascular changes in nor-
mal kidney tissues can be attenuated by simultaneous treatment with
soy isoflavones, giving support to our hypothesis that soy could reduce
sunitinib-induced vascular damage in normal tissues.
The combination of sunitinib with tumor irradiation and soy iso-
flavones showed a dramatic inhibition of tumor growth, disruption of
vasculature, and tumor cell destruction in kidney tumors. The mecha-
nisms of interaction between antiangiogenic agents and ionizing radiation
could involve interactions between tumor stroma and vasculature and
the tumor cells [33,34]. Combining radiotherapy with angiogenic in-
hibitors showed increased antitumor efficacy in animal tumor models
owing to increased toxicity to endothelial cells and tumor vasculature.
Inhibition of VEGFR-2 signaling by RTK inhibitors or anti–VEGFR-2
Abs enhanced response to radiotherapy in subcutaneous tumors in ani-
mal tumor models [35,36]. The role of hypoxia in radioresistance of
tumors and angiogenesis could involve poor tumor oxygenation but
also up-regulation of hypoxia-inducible factor (HIF-1α) as a cellular
response to stress and damage induced by radiation [34]. Although ra-
diation causes vascular damage in tumors, we and others have shown
that radiation activates survival pathways in cancer cells including up-
regulation of HIF-1α and NF-κB activities, which are both transcrip-
tion factors responsible for VEGF gene transcription [24,26]. This
could trigger a vicious cycle of de novo angiogenesis in residual tumor
areas in which tumor cells were not destroyed by radiation, leading to
tumor recurrence.We have previously demonstrated that soy isoflavones
inhibit up-regulation ofHIF-1α andNF-κB induced by irradiation, and
we surmise that this mechanism could further enhance the antitumor
response of kidney tumors as suggested by our studies.
We conclude that an antiangiogenic approach, which only partially
destroys inefficient vessels, could potentially increase the efficacy and
delivery of cytotoxic therapies and radiotherapy for unresectable primary
RCC tumors and metastatic disease.
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